PreCheck Pilot Program Structure

Why It Matters

By front‑loading facility assessments, PreCheck reduces regulatory delays, bolstering domestic drug supply resilience and cutting time‑to‑market for new therapies.

Key Takeaways

• PreCheck provides early FDA feedback through structured Pre‑Operational Reviews
• Type V DMF serves as a single, reusable facility information repository
• Phase 2 uses Phase 1 data for expedited pre‑submission meetings
• Participants receive a dedicated FDA point of contact throughout
• Program aims to accelerate inspections and shorten drug approval timelines

Pulse Analysis

The FDA’s PreCheck Pilot Program is a strategic response to chronic drug‑supply bottlenecks, offering manufacturers a clear, two‑phase roadmap to bring new production sites online faster. Phase 1 focuses on early engagement, where the agency conducts Pre‑Operational Reviews that scrutinize design concepts, construction plans, equipment qualification, and pre‑production readiness. Simultaneously, manufacturers compile a Type V Drug Master File—a confidential, centralized dossier that captures all facility‑related data. This "qualify once, reference many" approach eliminates repetitive submissions, ensuring that critical design decisions are vetted before costly construction begins.

In Phase 1, the POR process provides real‑time, actionable feedback, allowing firms to correct design flaws before they become entrenched. The Type V DMF becomes a living document, updated as the facility evolves, and serves as the factual backbone for later regulatory interactions. By consolidating facility information, the program reduces the FDA’s review workload and gives manufacturers confidence that their quality systems meet CGMP standards from day one. The integrated model also creates a transparent audit trail, facilitating smoother handoffs to downstream product applications.

Transitioning to Phase 2, the pre‑submission meetings leverage the rich data set already vetted in Phase 1, enabling the FDA to conduct earlier, more informed inspections and to fast‑track the Chemistry, Manufacturing and Controls (CMC) review component of NDAs, ANDAs, or BLAs. This front‑loading of facility assessment can shave weeks or months off the overall approval timeline, especially for subsequent products using the same site. For the industry, PreCheck promises not only faster market entry but also a more predictable regulatory environment, strengthening the United States’ capacity to meet domestic drug demand.